Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

$846,595 $661,982

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of Projected GAAP Basic Income per Common Share

to Basic Adjusted Income Per Common Share Guidance

(Unaudited)

Twelve Months Twelve Months

Ended Ended

December 31, 2008 December 31, 2009

Projected GAAP basic income per common

share $4.41 - $4.51 $4.95 - $5.05

Amortization of current intangibles $1.48 - $1.48 $1.36 - $1.36

Accelerated depreciation adjustment-

CIMA $0.10 - $0.10 $0.09 - $0.09

Accelerated depreciation adjustment-

Mitry-Mory $0.10 - $0.10 $0.24 - $0.24

Cost of goods sold adjustments $0.38 - $0.38 $- - $-

Research and development adjustments $0.12 - $0.12 $- - $-

Selling, general and administrative

adjustments $0.44 - $0.44 $- - $-

Settlement reserve adjustments $0.11 - $0.11 $- - $-

In-process research and development

adjustment $0.15 - $0.15 $- - $-

Restructuring adjustments $0.12 - $0.12 $0.07 - $0.07

Interest expense adjustment $0.17 - $0.17 $- - $-

Interest expense adjustment for

APB 14-1 $- - $- $0.63 - $0.63

Tax effect of pre-tax adjustments at

the applicable tax rates $(2.38)- $(2.38) $(0.84)- $(0.84)

Basic adjusted income per common share

guidance $5.20 - $5.30 $6.50 - $6.6
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... 2015  Discovery Laboratories, Inc. (Nasdaq: DSCO ... second $1.0M tranche under a previously awarded Phase ... at up to $3.0 million to support continued ... a potential medical countermeasure to mitigate acute and ... an initial $1.0 million under this grant in ...
(Date:7/29/2015)... 2015 According to a new market ... & Forecasts (2015-2020), , published by Mordor Intelligence, the Global ... the end of 2020, with North America ... 40% of the global market size. The Global market for ... 13.7% during the period of (2015-2020).      (Logo: ...
(Date:7/29/2015)...  AsureQuality and Ubiquitome have agreed to collaborate ... food and primary production sectors. The collaboration will ... the Freedom4. AsureQuality provides quality assurance ... shelf for producers, processors and Competent Authorities around ... control and pest management and surveillance programmes. ...
Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... Md., Sept 10 Spherix Incorporated (Nasdaq: SPEX ... provider of technical and regulatory consulting services to food, supplement, ... 2009, Ram R. Nimmagudda, Ph.D., has joined the company as ... Dr. Nimmagudda brings to Spherix more than 15 years of ...
... IRVINE, Calif., Sept. 10 ISTA Pharmaceuticals, Inc. ... at the NewsMakers in the Biotech Industry Conference at 11:30 ... Broadway Hotel in New York, NY. , , ... Development Lauren Silvernail will provide an update on the Company,s ...
... , COLUMBIA, Md., Sept. 10 Cylex, ... and manufactures research and in vitro diagnostic ... of the company,s president, Brad L. Stewart, to chief ... joining Cylex as president in December 2007, Mr. Stewart ...
Cached Biology Technology:Spherix Incorporated Appoints Dr. Ram Nimmagudda As Director of New Business Development 2Spherix Incorporated Appoints Dr. Ram Nimmagudda As Director of New Business Development 3Spherix Incorporated Appoints Dr. Ram Nimmagudda As Director of New Business Development 4Cylex, Inc. Appoints Brad L. Stewart as Chief Executive Officer and Chairman of the Board 2Cylex, Inc. Appoints Brad L. Stewart as Chief Executive Officer and Chairman of the Board 3Cylex, Inc. Appoints Brad L. Stewart as Chief Executive Officer and Chairman of the Board 4
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. ... molecular diagnostics, today announced the launch of a ... Company,s Precision Cancer Monitoring℠ (PCM) technology for predicting ... one or a combination of the novel immunotherapy ... (nivolumab), a PD-1 inhibitor. The 50-patient study will ...
(Date:7/7/2015)... 7, 2015  Based on its recent analysis ... recognizes Credence ID, LLC with the 2015 Asia-Pacific ... the Year Award. Credence ID has developed a ... mission of offering enrollment and identification solutions to ... ID was formed by experts from the mobile ...
(Date:7/2/2015)... , June 25, 2015 ... addition of the "Next Generation Biometrics Market by ... 2020" report to their offering. The ... Billion by 2020, at a CAGR of 17.9% between ... the leading application for the market. Safran SA ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... the same sweaty man smells pleasant to one person ... genes. Duke University Medical Center researchers demonstrated that ... how a particular odor is perceived. The researchers, led ... genetics and microbiology, published the results of their experiments ...
... have found the origins of an odor the sweet ... team shows that the protein that makes geosmin source ... distinct halves, each playing a critical role in making this ... of warm earth, said David Cane, professor of chemistry at ...
... among the leaders in a worldwide effort to revolutionize ... in the field with a technique called DNA barcoding. ... the grocery store, a DNA barcode is used to ... scientists are gathering in Taiwan for the Second International ...
Cached Biology News:Genetic variant linked to odor perception 2Good earth: Brown chemists show origin of soil-scented geosmin 2Smithsonian scientists help lead effort to 'barcode' world's species 2Smithsonian scientists help lead effort to 'barcode' world's species 3
... are a mixture of Strep•Tag® II fusion ... The markers provide precise size references for ... Coomassie blue. Because each of the proteins ... can also be detected by the Strep•Tag ...
Mouse monoclonal antibody to ACP2 - acid phosphatase 2, lysosomal...
... platform, 220 V, is used for agitation and ... cultures, staining and destaining of gels and blots, ... control (8-40 rpm) and can handle a maximum ... features two 29 x 21 cm platforms covered ...
... Acid) Clear to very pale yellow ... 2 O 2 in a citrate buffer ... is soluble, safe, convenient and has good overall ... blue-green color that can be measured at 405 ...
Biology Products: